Cingulate is a clinical stage biopharmaceutical company focused on the development of innovative new product candidates for the treatments of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety associated disorders.
Cingulate is developing ADHD medications capable of achieving precise once-daily dosing using a novel erosion based controlled release technology that provides unrivaled control of drug release.
Cingulate currently has two (2) product candidates, CTX-1301 and CTX-1302, that are being developed to serve the approximate $18 billion annual U.S. ADHD market. A third product candidate, CTX-2103, is being developed to serve the roughly $5 billion U.S. anxiety market.
Cingulate® (CTx®) is a biopharmaceutical company focused on the development of new product candidates for the treatment of central nervous system and neurobiological disorders.
PIPELINE
Cingulate® currently has two product candidates for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
ADHD
Attention Deficit/Hyperactivity Disorder (ADHD) is a chronic neurobiological and developmental disorder that affects millions of children and often continues into adulthood.
The Precision Timed Release™ Platform
The Precision Timed Release™ Platform is a triad of proprietary, sophisticated elements